Dr. Anjali Vaidya Provides Perspective to Healio on New Pulmonary Arterial Hypertension Study

Anjali Vaidya, MD, FACC, FASE, FACP, Co-Director of the Pulmonary Hypertension, Right Heart Failure & Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program at Temple University Hospital, provided perspective to Healio on findings presented at the 2025 International Society for Heart and Lung Transplantation Annual Meeting that found Among patients with pulmonary arterial hypertension treated with selexipag, the 10-year survival rate was 60%.